Rallybio Corp

Stock Chart, Company Information, and Scan Results

$0.57(as of Oct 8, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Rallybio Corp Company Information, Fundamentals, and Technical Indicators

Stock Price$0.57
Ticker SymbolRLYB
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees20
CountyUSA
Market Cap$24.0M
EBIDTA-41.6M
10-Day Moving Average0.55
P/E Ratio-0.60
20-Day Moving Average0.57
Forward P/E Ratio0.00
50-Day Moving Average0.56
Earnings per Share-0.93
200-Day Moving Average0.56
Profit Margin-4,576.89%
RSI49.71
Shares Outstanding41.8M
ATR0.05
52-Week High1.24
Volume156,502
52-Week Low0.22
Most Recent Support Level0.48
Book Value46.0M
Most Recent Resistance Level0.60
P/B Ratio0.55
Upper Keltner0.67
P/S Ratio33.00
Lower Keltner0.47
Debt-to-Equity Ratio0.67
Next Earnings Date11/06/2025
Cash Surplus4.4M
Next Ex-Dividend DateUnknown

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Rallybio Corp In Our Stock Scanner

As of Oct 09, 2025
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Golden CrossScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.